Fax: (919) 668-1091
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
Version of Record online: 16 APR 2004
Copyright © 2004 American Cancer Society
Volume 100, Issue 11, pages 2408–2414, 1 June 2004
How to Cite
Rizzieri, D. A., Sand, G. J., McGaughey, D., Moore, J. O., DeCastro, C., Chao, N. J., Vredenburgh, J. J., Gasparetto, C., Long, G. D., Anderson, E., Foster, T., Toaso, B., Adams, D., Niedzwiecki, D. and Gockerman, J. P. (2004), Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer, 100: 2408–2414. doi: 10.1002/cncr.20245
- Issue online: 18 MAY 2004
- Version of Record online: 16 APR 2004
- Manuscript Accepted: 4 MAR 2004
- Manuscript Revised: 26 FEB 2004
- Manuscript Received: 16 JAN 2004
- Bristol-Myers-Squibb, Inc.
- Gaston County Medical Society
- non-Hodgkin lymphoma (NHL);
Many patients with recurrent, intermediate or high-grade non-Hodgkin lymphoma (NHL) may not respond to or are not candidates for aggressive salvage chemotherapy. Effective, less toxic regimens are needed. Although high-dose taxanes have not been reported to be very effective for the treatment of lymphoma, different delivery rates may allow for different mechanisms of action to be manifest and result in a different toxicity profile and response rate. The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL.
Adults age > 18 years with refractory or recurrent, aggressive NHL who were not considered curable with standard high-dose therapy received paclitaxel at a dose of 80 mg/m2 weekly for 5 weeks for 2 cycles.
Thirty-four patients with refractory NHL and 4 patients with recurrent disease were treated. Approximately 45% of the patients had achieved a prior disease remission. The median number of prior regimens received was 3, 74% of the patients had an International Prognostic Index of ≥ 3 at the time of study entry, and 29% had failed high-dose therapy with autologous hematopoietic support. Only one patient encountered severe toxicity (sepsis). Myelosuppression was reported to occur in approximately 20% of patients. A total of 10 patients (26%) achieved a complete disease response and 4 patients (11%) achieved a partial response.
In the current study, low-dose, weekly paclitaxel therapy was found to provide a well tolerated and less toxic approach to the treatment of refractory NHL, with encouraging responses noted in heavily pretreated patients. However, evaluation in patients with an earlier stage of disease is warranted. Cancer 2004. © 2004 American Cancer Society.